Figure 2
From: Repositioning: the fast track to new anti-malarial medicines?
In vivo efficacy of (A) AZ-1 and (B) AZ-3 candidate drugs in Plasmodium berghei -infected mice. Study performed by AstraZeneca. Male BALB/c (n = 3) mice infected with P. berghei intraperitoneally were treated simultaneously with different dose groups of compounds and controls for four days starting from day 0. The percentage growth inhibition on final day was plotted against different groups. P values are versus untreated controls.